首页> 外文期刊>Journal of peptide science: An official publication of the European Peptide Society >Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V-2/V-1b receptor selectivity
【24h】

Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V-2/V-1b receptor selectivity

机译:[deamino-Cys(1)]精氨酸升压素的位置4类似物在人类和大鼠V-2 / V-1b受体选择性上表现出惊人的物种差异

获取原文
获取原文并翻译 | 示例
           

摘要

Arginine vasopressin (AVP) mediates a wide variety of biological actions by acting on three distinct G-protein coupled receptors, termed V-1a (vascular), V-1b, (pituitary) and V-2 (renal). It also binds to the oxytocin (OT) receptor. As part of a program aimed at the design of selective agonists for the human V-1b receptor, we recently reported the human V-1b, V-1a, V-2 and OT receptor affinities of the following position 4 substituted analogues of [deamino-Cys(1)] arginine vasopressin (dAVP) - (1) d[Leu(4)]AVP, (2) d[Orn(4)]AVP, (3) d[Lys(4)]AVP. (4) d[Har(4)]AVP, (5) d[Arg(4)]AVP, (6) d[Val(4)]AVP. (7) d[Ala(4)]AVP. (8) d[Abu(4)]AVP, (9) d[Nva(4)]AVP, (10) d[Nle(4)]AVP. (11) d[IIe(4)]AVP. (12) d[Phe(4)]AVP. (13) d[Asn(4)]AVP. (14) d[Thr(4)]AVP: (15) d[Dap(4)]AVP. With the exception of Nos. 7 and 12, all peptides exhibit very high affinities for the human VIb receptor. Furthermore, peptides 1-4 exhibit high selectivities for the human VIb receptor with respect to the Via, V-2 and OT receptors and, with d[Cha(4)]AVP, in functional tests, are the first high affinity selective agonists for the human V-1b, receptor (Cheng LL et at., J. Med. Chem. 47: 2375-2388, 2004). We report here the pharmacological properties of peptides 1-4. 5 (from a resynthesis), 7, 9-13. 15 in rat bioassays (antidiuretic, vasopressor and oxytocic) (in vitro: no Mg++) with those previously reported for peptides 5, 6, 8, 14. We also report the rat V-1b. V-1a, V-2 and OT receptor affinities of peptides 1-5 and the rat V-2 receptor affinities for peptides: 7-15.
机译:精氨酸加压素(AVP)通过作用于三种不同的G蛋白偶联受体(称为V-1a(血管),V-1b(垂体)和V-2(肾))介导多种生物学作用。它还与催产素(OT)受体结合。作为针对人V-1b受体选择性激动剂设计计划的一部分,我们最近报道了以下[deamino] 4位取代类似物的人V-1b,V-1a,V-2和OT受体亲和力-Cys(1)]精氨酸加压素(dAVP)-(1)d [Leu(4)] AVP,(2)d [Orn(4)] AVP,(3)d [Lys(4)] AVP。 (4)d [Har(4)] AVP,(5)d [Arg(4)] AVP,(6)d [Val(4)] AVP。 (7)d [Ala(4)] AVP。 (8)d [Abu(4)] AVP,(9)d [Nva(4)] AVP,(10)d [Nle(4)] AVP。 (11)d [IIe(4)] AVP。 (12)d [Phe(4)] AVP。 (13)d [Asn(4)] AVP。 (14)d [Thr(4)] AVP:(15)d [Dap(4)] AVP。除7和12号外,所有肽均对人VIb受体表现出非常高的亲和力。此外,相对于Via,V-2和OT受体,肽1-4对人VIb受体表现出高选择性,并且在功能测试中,与d [Cha(4)] AVP结合使用时,它是第一个针对该受体的高亲和力选择性激动剂人V-1b受体(Cheng LL等人,J。Med。Chem。47:2375-2388,2004)。我们在这里报告肽1-4的药理特性。 5(来自重新合成),7、9-13。大鼠生物测定(抗利尿药,血管加压药和催产药)中的15种(体外:无Mg ++)与先前报道的肽5、6、8、14的生物测定相同。我们还报告了大鼠V-1b。肽1-5的V-1a,V-2和OT受体亲和力和肽的大鼠V-2受体亲和力:7-15。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号